Nothing Special   »   [go: up one dir, main page]

DK1213972T3 - Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen - Google Patents

Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen

Info

Publication number
DK1213972T3
DK1213972T3 DK00958855T DK00958855T DK1213972T3 DK 1213972 T3 DK1213972 T3 DK 1213972T3 DK 00958855 T DK00958855 T DK 00958855T DK 00958855 T DK00958855 T DK 00958855T DK 1213972 T3 DK1213972 T3 DK 1213972T3
Authority
DK
Denmark
Prior art keywords
sugars
alpha
physiologically acceptable
acceptable compound
amylase inhibitor
Prior art date
Application number
DK00958855T
Other languages
English (en)
Inventor
Nils Christian Mortensen
Original Assignee
Med Eq As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Eq As filed Critical Med Eq As
Application granted granted Critical
Publication of DK1213972T3 publication Critical patent/DK1213972T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
DK00958855T 1999-09-08 2000-09-08 Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen DK1213972T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (1)

Publication Number Publication Date
DK1213972T3 true DK1213972T3 (da) 2003-08-18

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00958855T DK1213972T3 (da) 1999-09-08 2000-09-08 Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen

Country Status (14)

Country Link
EP (1) EP1213972B1 (da)
JP (1) JP2003508467A (da)
KR (1) KR100594520B1 (da)
AT (1) ATE238689T1 (da)
AU (1) AU777044B2 (da)
CA (1) CA2383720A1 (da)
DE (1) DE60002484T2 (da)
DK (1) DK1213972T3 (da)
ES (1) ES2199174T3 (da)
GB (2) GB9921229D0 (da)
NO (1) NO314922B1 (da)
NZ (1) NZ518167A (da)
PT (1) PT1213972E (da)
WO (1) WO2001017369A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス
WO2009112054A1 (en) * 2008-03-10 2009-09-17 Phf S.A. High bioavailability formulation of mangosteen and manufacturing process thereof
JP2012516842A (ja) * 2009-02-02 2012-07-26 ライラ ニュートラシューティカルズ 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
WO2016042517A1 (en) * 2014-09-19 2016-03-24 Nestec Sa Methods and formulations for reducing absorption of carbohydrates in a companion animal
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
KR20010101594A (ko) * 1999-01-22 2001-11-14 훈자 디 마리아 카르멜라 마라찌타 에스.아.에스. 지단백질 복합체 및 이를 함유하는 조성물

Also Published As

Publication number Publication date
DE60002484D1 (de) 2003-06-05
GB0127158D0 (en) 2002-01-02
ATE238689T1 (de) 2003-05-15
AU777044B2 (en) 2004-09-30
AU7026900A (en) 2001-04-10
NZ518167A (en) 2003-03-28
NO20021160L (no) 2002-03-27
CA2383720A1 (en) 2001-03-15
NO314922B1 (no) 2003-06-16
GB9921229D0 (en) 1999-11-10
GB2364498A (en) 2002-01-30
JP2003508467A (ja) 2003-03-04
KR20020045605A (ko) 2002-06-19
PT1213972E (pt) 2003-09-30
NO20021160D0 (no) 2002-03-08
EP1213972B1 (en) 2003-05-02
DE60002484T2 (de) 2004-03-18
WO2001017369A1 (en) 2001-03-15
KR100594520B1 (ko) 2006-07-19
EP1213972A1 (en) 2002-06-19
ES2199174T3 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
DK1213972T3 (da) Komposition omfattende en alfa-amylase-inhibitor og mindst en fysiologisk acceptabel forbindelse, der kan nedsætte absorptionen af "hurtigere sukkere" i tarmen
BG104680A (en) Celecoxib compositions
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
ATE551988T1 (de) Orale zusammensetzungen, ihre herstellung und verwendung
AU2002256093A1 (en) Bulking agents as satiety agents
PT1075258E (pt) Analogos gordos novos para o tratamento da obesidade
WO2004022074A8 (en) Nutritional compositions comprising a non-glucose carbohydrate or pectin and soluble fiber
TR200100448T2 (tr) Fenil ksantin türevleri
HRP20041132A2 (en) 7-aryl-3, 9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
HRP20050307A2 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
RS20050470A (en) Solid drug for oral use
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
IL156827A (en) Derivatives of 2-mercapto- [3,1] thiazolo [4,5 [b- pyridine and pharmaceutical preparations containing them for the treatment of cardiovascular disease
EA200701068A1 (ru) Применение антиоксидантных соединений для восстановления мышц
GB2421241A (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
WO2004000045A3 (en) Liquid compositions comprising non-digestible oligosaccharides and green tea catechins, method and uses thereof
JP2003508467A5 (da)
AU2003280314A1 (en) Composition for the treatment of gastrointestinal disorders
MXPA02011940A (es) Estuches y metodos para optimizar la eficacia de composiciones condroprotectoras.
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
NO20023640D0 (no) Fremgangsmåte for opprettholdelse av eller forbedring av syntese av muciner
SI1492521T1 (sl) Kombinirana uporaba l-karnitina, acetil l-karnitina in propil l-karnitina za zdravljenje oligoastenoteratospermije
IS6676A (is) Amínóalkenýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
RS20050272A (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2003077831A3 (en) Compositions and methods for treating mdma-induced toxicity